




FALL 2023 INVESTOR CONFERENCE

OCTOBER 17, 2023 | [LYTHAMPARTNERS.COM/VIRTUAL](https://lythampartners.com/virtual)



VIRTUAL CONNECTIONS. REAL VALUE.



WELCOME TO THE LYTHAM PARTNERS FALL 2023 INVESTOR CONFERENCE

ABOUT LYTHAM PARTNERS

Lytham Partners is one of the country's leading investor relations firms. With more than two decades of Corporate Access experience, we have built one of the industry's most diverse and effective platforms for connecting small cap companies with high quality and focused institutional investors.

ABOUT OUR CONFERENCES

The Lytham Partners Investor Conference Series creates value for small cap companies through virtual connections with high-quality institutional investors. Our conference series has featured more than 200 companies across various industries.

REQUEST 1X1 MEETINGS

CONNECT WITH US

We are excited to connect with our audience and share this virtual event online. Follow Lytham Partners IR on LinkedIn and [click here](#) to RSVP to our event page to stay updated on the latest conference news.




#lythamfall2023





PARTICIPATING COMPANIES

 = Webcast Presentation




BASIC MATERIALS

-  Arianne Phosphate (TSXV: DAN / OTCQX: DRRSF)
- E3 Lithium (TSXV: ETL / OTCQX: EEMMF)
- Nouveau Monde Graphite (NYSE: NMG / TSXV: NOU)
-  Volt Lithium Corp. (TSXV: VLT / OTCQB: VLTLF)

CONSUMER

- Charles & Colvard (NASDAQ: CTHR)
-  Else Nutrition Holdings (TSXV: BABY / OTCQX: BABYF)
-  Flow Beverage Corp. (TSX: FLOW / OTCQX: FLWBF)
- Jushi Holdings Inc. (CSE: JUSH / OTCQX: JUSHF)

ENERGY

- Riley Exploration Permian, Inc. (NYSE American: REPX)
-  Saturn Oil & Gas Inc. (TSX: SOIL / OTCQX: OILSF)

FINTECH

-  Mogo Inc. (TSX: MOGO / NASDAQ: MOGO)
- WonderFi Technologies Inc. (TSX: WNDR / OTCQB: WONDF)


INDUSTRIALS

- Anterix (NASDAQ: ATEX)
- Global Bioenergies (Euronext Growth: ALGBE)
- GSE Systems, Inc. (NASDAQ: GVP)
- LiqTech International, Inc. (NASDAQ: LIQT)
- Northern Technologies Intl. Corp. (NASDAQ: NTIC)
-  S&W Seed Company (NASDAQ: SANW)
-  SenesTech Inc. (NASDAQ: SNES)

HEALTHCARE

- aTyr Pharma (NASDAQ: LIFE)
- Aurora Spine Corporation (TSXV: ASG / OTCQB: ASAPF)
-  Aytu BioPharma, Inc. (NASDAQ: AYTU)
- Azitra Inc. (NYSE American: AZTR)
-  Cadrenal Therapeutics (NASDAQ: CVKD)
- Clene Inc. (NASDAQ: CLNN)
-  Delcath Systems (NASDAQ: DCTH)
- electroCore, Inc. (NASDAQ: ECOR)
- Hamilton Thorne Ltd. (TSXV: HTL)
-  Hydrecht Technologies (TSXV: NURS / OTCQB: HYDTF)
- ImmuCell Corp. (NASDAQ: ICCG)
-  INVO Bioscience (NASDAQ: INVO)
-  Jaguar Health, Inc. (NASDAQ: JAGX)
-  Kiora Pharmaceuticals (NASDAQ: KPRX)
- Modular Medical, Inc. (NASDAQ: MODD)
- OpSens Inc. (TSX: OPS / OTCQX: OPSSF)
- Organovo Holdings, Inc. (NASDAQ: ONVO)
-  Reliq Health Technologies Inc. (TSXV: RHT / OTC PINK: RQHTF)
-  Reviva Pharmaceuticals Holdings (NASDAQ: RVPH)
- Scientific Industries, Inc. (OTCQB: SCND)
-  Shuttle Pharmaceuticals, Inc. (NASDAQ: SHPH)
- SOBR Safe, Inc. (NASDAQ: SOBR)
- Windtree Therapeutics, Inc. (NASDAQ: WINT)
-  Zomedica Corp. (NYSE American: ZOM)

TECHNOLOGY

-  Edge Total Intelligence (TSXV: CTRL / OTCQB: UNFYF)
- Legible (CSE: READ / OTCQB: LEBGF)
-  LiveWorld, Inc. (OTC PINK: LVWD)
-  Precision Optics Corporation (NASDAQ: POCI)
-  QuickLogic Corporation (NASDAQ: QUIK)
- SKYX Platforms Corp. (NASDAQ: SKYX)
-  Society Pass Incorporated (NASDAQ: SOPA)
- VERSES AI Inc. (CBOE: VERS / OTCQX: VRSSF)
-  Zoomd Technologies (TSXV: ZOMD / OTC PINK: ZMDTF)

This list has been updated as of September 25, 2023. Participation subject to change.


CONTACT US!

For more information on our Fall 2023 Investor Conference, please call 602.889.9700 or email us at conference@lythampartners.com



COMPANY PROFILES

Market Cap data (\$USD) updated as of 9.1.23



ANTERIX (NASDAQ: ATEX)

Industrials | Market Cap: \$900M

Anterix enables critical infrastructure and enterprise to transform their businesses through the power of private wireless broadband connectivity on 900 MHz spectrum. Our foundational spectrum allows for greater risk mitigation with increased cyber security, resiliency and control.

ARIANNE PHOSPHATE (TSXV: DAN / OTCQX: DRRSF)

Basic Materials | Market Cap: \$59M

Arianne Phosphate is development-stage phosphate mining company, advancing the Lac à Paul project in Quebec's Saguenay-Lac-Saint-Jean region. Arianne Phosphate is the only large-scale source of independent phosphate rock from a low-risk jurisdiction projected to come onstream over the next few years. We offer very high-quality apatite (phosphate) concentrate containing approximately 39% P₂O₅ with very few contaminants. With a mining and investment-friendly jurisdiction and a well-developed infrastructure in a stable and supportive environment, Arianne Phosphate presents a lucrative opportunity to fulfill the world's growing demand for phosphate.

ATYR PHARMA (NASDAQ: LIFE)

Healthcare | Market Cap: \$106M

aTyr Pharma (Nasdaq: LIFE) is a clinical stage biotechnology company working to translate tRNA synthetase biology into new therapies for inflammation and fibrosis. aTyr's lead therapeutic candidate, efzofitimid, is a first-in-class biologic immunomodulator that downregulates innate immune responses in uncontrolled inflammatory disease states. aTyr is developing efzofitimid as a potential disease-modifying therapy to resolve chronic inflammation and prevent the progression of fibrosis in forms of interstitial lung disease (ILD). aTyr is currently conducting EFZO-FIT™, a global pivotal Phase 3 study of efzofitimid in pulmonary sarcoidosis, the most prevalent form of ILD, and is planning to initiate EFZO-CONNECT™, a Phase 2 study in patients with SSC-ILD, in 2023.

AURORA SPINE CORPORATION (TSXV: ASG / OTCQB: ASAPF)

Healthcare | Market Cap: \$18M

Aurora Spine is an emerging growth company focused on bringing new solutions to the spinal implant market through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Aurora Spine continues to position itself at the forefront of spinal surgery procedures, focusing on minimally invasive spine surgery technologies. Aurora Spine is changing spine surgery by focusing on disruptive technologies following the Company's commitment to – Simplifying the Complex.

AYTU BIOPHARMA, INC. (NASDAQ: AYTU)

Healthcare | Market Cap: \$9M

Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotelma XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu's consumer health segment markets a range of over-the-counter medicines and consumer health products addressing a range of common conditions including diabetes, allergy, hair regrowth, and gastrointestinal conditions.

AZITRA INC. (NYSE AMERICAN: AZTR)

Healthcare | Market Cap: \$32M

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of *Staphylococcus epidermidis*, or *S. epidermidis*, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit <https://azitrainc.com/>.

CADRENAL THERAPEUTICS (NASDAQ: CVKD)

Healthcare | Market Cap: \$12M

Cadrenal Therapeutics is focused on developing tecarfarin, a novel cardiorenal therapy with orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2 and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with CKD.

CHARLES & COLVARD, LTD. (NASDAQ: CTHR)


Consumer | Market Cap: \$24M

Charles & Colvard (Nasdaq: CTHR) believes fine jewelry can be accessible, beautiful and conscientious. Charles & Colvard is the original pioneer of lab-created moissanite, a rare gemstone formed from silicon carbide. The Company brings revolutionary gemstones and jewelry to market through its pinnacle Forever One™ moissanite brand and its premium Caydia™ lab grown diamond brand. Consumers seek Charles & Colvard fashion, bridal and fine jewelry because of its exceptional quality, incredible value and shared beliefs in environmental and social responsibility. Charles & Colvard was founded in 1995 and is based in North Carolina's Research Triangle Park.



COMPANY PROFILES

Market Cap data (\$USD) updated as of 9.1.23



CLENE INC. (NASDAQ: CLNN)

Healthcare | Market Cap: \$93M

Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.

DEL CATH SYSTEMS (NASDAQ: DCTH)

Healthcare | Market Cap: \$51M

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO Kit is considered an investigational drug/device combination product regulated as a drug by the United States Food and Drug Administration (FDA). HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtering hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. In the US, HEPZATO Kit was the subject of a February 14, 2023 new drug application resubmission to FDA for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM), also known as metastatic uveal melanoma (mUM). FDA has established an August 14, 2023 PDUFA date for the resubmission. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

E3 LITHIUM (TSXV: ETL / OTCQX: EEMMF)

Basic Materials | Market Cap: \$200M

E3 Lithium is Canada's leading lithium developer aiming to power the growing electric vehicle revolution. We are focused on creating long-term, sustainable value for the future by creating a world-class, large-scale, long-life lithium production company. With our focus on safe operations, strong financial position and world-class asset base, we are poised to lead the development of Canada's lithium industry.

EDGE TOTAL INTELLIGENCE (TSXV: CTRL / OTCQB: UNFYF)

Technology | Market Cap: \$16M

edgeTI helps customers sustain situational awareness and accelerate action with its real-time digital operations software, edgeCore™ that unites multiple software applications and data sources into one immersive experience. Global enterprises, service providers, and governments are more profitable when insight and action are united to deliver fluid journeys via the platform's low-code development capability and composable operations. With edgeCore, customers improve their margins and agility by rapidly transforming siloed systems and data across continuously evolving situations in business, technology, and cross-domain operations — helping them achieve the impossible.

ELECTROCORE, INC. (NASDAQ: ECOR)

Healthcare | Market Cap: \$33M

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation ("nVNS") technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

ELSE NUTRITION HOLDINGS (TSXV: BABY / OTCQX: BABYF)

Consumer | Market Cap: \$41M

Else Nutrition Holdings Inc. is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at Milan's Global Food Innovation Summit. The holding company, Else Nutrition Holdings Inc., is a publicly-traded company, listed on TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets Q.X. board under the trading symbol BABYF and the Frankfurt Exchange under the symbol OYL. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents and gained national retailer support from Sprouts Farmers Market, and achieved rapid sales growth. Else became the #1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler Formula Category. It recently won the 'Best Dairy Alternative' Award 2021 at World Plant-Based Expo and was a Nexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle category.

FLOW BEVERAGE CORP. (TSX: FLOW / OTCQX: FLWBF)


Consumer | Market Cap: \$13M

Flow is one of the fastest-growing premium water companies in North America. Founded in 2014, Flow's mission since day one has been to reduce environmental impacts by providing sustainably sourced naturally alkaline spring water in a recyclable and up to 75% renewable, plant-based pack. Today, the brand is B-Corp Certified with a best-in-class score of 126.5, offering a diversified line of health and wellness-oriented beverage products: original naturally alkaline spring water, award-winning organic flavours, collagen-infused and vitamin-infused flavours in sizes ranging from 330-ml to 1-litre. All products contain naturally occurring electrolytes and essential minerals and support Flow's overarching purpose to "bring wellness to the world through the positive power of water." Flow beverage products are available online at flowhydration.com and are sold at over 46,000 stores across North America.



COMPANY PROFILES

Market Cap data (\$USD) updated as of 9.1.23



GLOBAL BIOENERGIES (EURONEXT GROWTH: ALGBE)

Industrials | Market Cap: \$57M

Global Bioenergies offers a renewable alternative to oil-based derivatives by producing chemical compounds from plant residues for use in many cutting-edge fields such as cosmetics and energy. These drop-in compounds have the same properties as oil-based products while improving carbon footprint and naturalness. Global Bioenergies' sustainable aviation fuel technology is one of the very few ASTM-certified technologies that can be used in any commercial aircraft worldwide. The Company's vision is to reduce CO2 emissions in the aviation sector and thereby curb global warming. Global Bioenergies is listed on Euronext Growth Paris.

GSE SYSTEMS, INC. (NASDAQ: GVP)

Industrials | Market Cap: \$11M

GSE Solutions leverages top talent, expertise, and technology to help energy facilities achieve next-level power plant performance. GSE's advanced Engineering and Workforce Solutions divisions offer highly specialized training, engineering design, program compliance, simulation, and technical staffing that reduce risk and optimize plant operations. With more than 1,100 installations and hundreds of customers in over 50 countries, GSE delivers operational excellence. www.gses.com

HAMILTON THORNE LTD. (TSXV: HTL)

Healthcare | Market Cap: \$212M

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

HYDREIGHT TECHNOLOGIES (TSXV: NURS / OTCQB: HYDTF)

Healthcare | Market Cap: \$9M

Hydreight Technologies Inc. (TSXV: NURS) is a telehealth platform and medical network enabling flexible home healthcare that bridges the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals to deliver services independently, on their own terms, or add mobile services to existing location-based operations. The network offers medical director oversight, liability insurance, HIPAA-compliant documentation, competitively priced prescriptions via a 503B licensed pharmacy, and more. The platform includes a built-in, easy-to-use suite of fully-integrated tools for accounting, documentation, sales, inventory, booking, managing patient data, and more, making it possible to deliver fully-compliant mobile medicine across 50 states. Learn more at Hydreight.com. Patients can download Hydreight from the Apple App store or Google Play Store, and prospective service providers can sign up at: Hydreight.com/start-a-business/

IMMUCELL CORPORATION (NASDAQ: ICCG)

Healthcare | Market Cap: \$37M

ImmuCell Corporation's (Nasdaq: ICCG) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics.

INVO BIOSCIENCE (NASDAQ: INVO)


Healthcare | Market Cap: \$2M

We are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. Our flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization ("IVF") and is a significantly more effective treatment than intrauterine insemination ("IUI"). Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), in addition to continuing to distribute and sell our technology solution into existing fertility clinics.



COMPANY PROFILES

Market Cap data (\$USD) updated as of 9.1.23



JAGUAR HEALTH, INC. (NASDAQ: JAGX)

Healthcare | Market Cap: \$10M

Jaguar Health is a commercial stage pharmaceuticals company that develops novel, plant-based, sustainably derived prescription medicines for GI distress. Our Mytesi® (crofelemer) product (tablet) is FDA-approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Our key near-term clinical activity is our ongoing Phase 3 pivotal OnTarget trial of crofelemer for our core follow-on indication of prophylaxis of cancer therapy-related diarrhea. We expect enrollment in this pivotal trial to complete in the second quarter of 2023. The trial is evaluating the effectiveness of crofelemer's novel mechanism of action – the modulation of two chloride ion channels in the gastrointestinal tract – to mitigate or substantially reduce chronic cancer therapy-related diarrhea. Jaguar's expectation is that this placebo-controlled trial will provide evidence that diarrhea associated with targeted cancer therapies is chronic, not acute, and impacts the patient's ability to remain on their cancer therapy regimens at proven doses for better outcomes. Each year, according to the CDC, more than 1 million cancer patients receive chemotherapy or radiation in an outpatient oncology clinic in the U.S. Treatment can last for months to years, in both the curative and metastatic situations. Crofelemer is currently approved for a chronic use in HIV/AIDS patients, providing a potential opportunity for a paradigm shift for prophylaxis of CTD compared to the management of severe chronic diarrhea with constipating agents such as antimotility drugs, which are predominantly opioids. The company's second prioritized clinical program centers around the evaluation of crofelemer for short bowel syndrome (SBS) with intestinal failure and for microvillus inclusion disease (MVID), a rare congenital diarrheal disorder (CDD). SBS with intestinal failure and MVID are devastating and often catastrophic diseases for patients, who are frequently on parenteral nutrition for as long as 20 hours a day, seven days a week. Jaguar and the company it established in Europe, Napo Therapeutics, are planning to support investigator-initiated proof-of-concept studies of crofelemer in patients with SBS with intestinal failure or MVID, focused on obtaining proof-of-concept (POC) of reduction of requirements of parenteral support including parenteral nutrition and/or intravenous fluids, in 2023. In accordance with the guidelines of specific European Union countries, publications of POC data from these trials could support early patient access to crofelemer for SBS with intestinal failure or MVID through programs in Europe. Early access programs are revenue generating, and reimbursable for participating patients. Crofelemer has been granted Orphan Drug Designation for SBS and MVID by both the FDA and the European Medicines Agency.

JUSHI HOLDINGS INC. (CSE: JUSH / OTCQX: JUSHF)

Consumer | Market Cap: \$83M

Jushi Holdings Inc. is a national, multi-state cannabis company developing and operating high-end retail locations, premium brands and state-of-the-art cultivation, processing and manufacturing facilities. Our platform is designed to set the new standard for a sophisticated, modern cannabis experience.

KIORA PHARMACEUTICALS (NASDAQ: KPRX)

Healthcare | Market Cap: \$3M

Kiora Pharmaceuticals (NASDAQ: KPRX) is a clinical-stage biotechnology company developing innovative therapies to treat rare retinal diseases like Retinitis Pigmentosa, Choroideremia, and Stargardt's Disease. The company's lead asset, KIO-301, is a first-in-class molecular photoswitch designed to restore vision in patients with inherited and age-related retinal degeneration. KIO-301 works by converting light signals in the eye into electrical signals that are transmitted to the brain. Kiora also plans to develop KIO-104 to treat non-infectious uveitis, an inflammatory eye condition.

LEGIBLE (CSE: READ / OTCQB: LEBGF)

Technology | Market Cap: \$25M

Legible is an online bookstore streaming 2 million eBooks & audiobooks to any device in the world, turning any smart device into an interactive library. Legible also uniquely offers & produces multimedia & AI-enhanced books, offering dynamic, personalized eBook entertainment & education at your fingertips.

LIQTECH INTERNATIONAL, INC. (NASDAQ: LIQT)

Industrials | Market Cap: \$19M

LiqTech International, Inc., a Nevada corporation, is a clean technology company that provides state-of-the-art ceramic silicon carbide filtration technologies for gas and liquid purification. LiqTech's silicon carbide membranes are designed to be used in the most challenging water purification applications, and its silicon carbide filters are used to control diesel exhaust soot emissions. Applying nanotechnology, LiqTech develops products using its proprietary silicon carbide technology, resulting in a wide range of component membranes, membrane systems, and filters for both microfiltration and ultrafiltration applications. By incorporating LiqTech's SiC liquid membrane technology with the Company's extensive systems design experience and capabilities, LiqTech offers unique, turnkey solutions for the most difficult water purification applications.

LIVEWORLD, INC. (OTC PINK: LVWD)

Technology | Market Cap: \$1M

LiveWorld is a full-service digital agency with deep social, creative, and compliance expertise that help companies spark emotional connections, build stronger customer relationships, and drive behavior change. We live at the intersection of bold creative rooted in strategy that inspires, moderation that activates human interactions, and technology that enriches and scales customer experiences. With over 26 years of making connections, our integrated team leverages our social media DNA to deliver emotion driven behavior change through digital campaigns with a human touch. LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld.

MODULAR MEDICAL, INC. (NASDAQ: MODD)


Healthcare | Market Cap: \$19M

Modular Medical is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent diabetes to receive their daily insulin in two ways, through a continuous "basal" delivery allowing a small amount of insulin to be in the blood at all times and a "bolus" delivery to address meal time glucose input and to address when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition, the Company believes it can address the less technically savvy, less motivated part of the market.



COMPANY PROFILES

Market Cap data (\$USD) updated as of 9.1.23



MOGO INC. (TSX: MOGO / NASDAQ: MOGO)

FinTech | Market Cap: \$137M

Mogo, one of Canada's leading digital finance companies, is empowering its members with simple digital solutions to help them build wealth and achieve financial freedom. Mogo's trade app, MogoTrade, offers commission-free stock trading that helps users make a positive impact with every investment and together with Moka, Mogo's wholly-owned subsidiary bringing automated, fully-managed flat-fee investing to Canadians, forms the heart of Mogo's digital wealth platform. Mogo also offers digital loans and mortgages. Through Mogo's wholly-owned subsidiary, Carta Worldwide, we also offer a digital payments platform that powers the next-generation card programs from innovative fintech companies in Europe and Canada. To learn more, please visit mogo.ca or download the mobile app (iOS or Android).

NORTHERN TECHNOLOGIES INTERNATIONAL CORPORATION (NASDAQ: NTIC)

Industrials | Market Cap: \$115M

Northern Technologies International Corporation develops and markets rust and corrosion inhibiting products and services in North America, South America, Europe, Asia, the Middle East and internationally. It offers rust and corrosion inhibiting products, such as plastic and paper packaging, liquids, coatings, rust removers, cleaners, diffusers, and engineered solutions designed for the oil and gas industry under the ZERUST brand. The company also provides a portfolio of bio-based and certified compostable polymer resin compounds and finished products under the Natur-Tec brand. In addition, it offers on-site and technical consulting for rust and corrosion prevention issues. The company sells its products and services to automotive, electronics, electrical, mechanical, military, retail consumer, and oil and gas markets through direct sales force, network of independent distributors and agents, manufacturer's sales representatives, and strategic partners. Northern Technologies International Corporation was founded in 1970 and is headquartered in Circle Pines, Minnesota.

NOUVEAU MONDE GRAPHITE (NYSE: NMG / TSXV: NOU)

Basic Materials | Market Cap: \$183M

Nouveau Monde Graphite is striving to become a key contributor to the sustainable energy revolution. The Company is working towards developing a fully integrated source of carbon-neutral battery anode material in Québec, Canada, for the growing lithium-ion and fuel cell markets. With enviable ESG standards, NMG aspires to become a strategic supplier to the world's leading battery and automobile manufacturers, providing high-performing and reliable advanced materials while promoting sustainability and supply chain traceability.

OPSENS INC. (TSX: OPS / OTCQX: OPSSF)

Healthcare | Market Cap: \$230M

OpSens Inc. (TSX: OPS) (OTCQX: OPSSF) a cardiology medical device company providing innovative product solutions based on its patented optical technology, focuses mainly on coronary artery stenosis measurement in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of more than 200,000 patients in more than 30 countries. It is approved for sale in the United States, the European Union, the United Kingdom, Japan and Canada. OpSens has recently received FDA clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement procedures (TAVR). This unique guidewire is a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access. OpSens' SavvyWire is on trend with a minimalist approach to TAVR and advances the procedure, allowing patients to leave the hospital earlier, sometimes the same day. The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is currently estimated at over 200,000 procedures and is expected to reach 400,000 in 2027. OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

ORGANOVO HOLDINGS, INC. (NASDAQ: ONVO)


Healthcare | Market Cap: \$13M

Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, 3D tissues that recapitulate key aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. The Company is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis ("UC") and Crohn's disease ("CD"). The Company intends to add additional tissues/diseases/targets to its portfolio over time. In line with these plans, the Company is building upon both its external and in house scientific expertise, which will be essential to its drug development effort. The Company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Organovo's advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. The Company's NovoGen Bioprinters® are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. The Company believes that the use of its bioprinting platform as well as complementary 3D technologies will allow it to develop an understanding of disease biology that leads to validated novel drug targets and therapeutics to those targets to treat disease. The majority of the Company's current focus is in inflammatory bowel disease ("IBD"), including CD and UC. The Company is creating high fidelity disease models, leveraging its prior work including the work found in its peer-reviewed publication on bioprinted intestinal tissues (Madden et al. Bioprinted 3D Primary Human Intestinal Tissues Model Aspects of Native Physiology and ADME/Tox Functions. iScience. 2018 Apr 27;2:156-167. doi:10.1016/j.isci.2018.03.015.) The Company's current understanding of intestinal tissue models and IBD disease models leads it to believe that it can create models that provide greater insight into the biology of these diseases than are generally currently available. Using these disease models, the Company intends to identify and validate novel therapeutic targets. After finding therapeutic drug targets, the Company intends to focus on developing novel small molecule, antibody, or other therapeutic drug candidates to treat the disease, and advance these novel drug candidates towards an Investigational New Drug ("IND") filing and potential future clinical trials. In March of 2023, the Company entered into and closed an asset purchase agreement with Metacrine, Inc to acquire their farnesoid X receptor ("FXR") program. FXR is a mediator of gastrointestinal ("GI") and liver diseases. FXR agonism has been tested in a variety of preclinical models of IBD. The acquired program contains two clinically tested compounds and over 2,000 discovery or preclinical compounds. The Company expects to broaden its work into additional therapeutic areas over time and is currently exploring specific tissues for development. In the Company's work to identify the areas of interest, it evaluates areas that might be better served with 3D disease models than currently available models as well as the potential commercial opportunity.



COMPANY PROFILES

Market Cap data (\$USD) updated as of 9.1.23



PRECISION OPTICS CORPORATION (NASDAQ: POCI)

Technology | Market Cap: \$36M

Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power.

QUICKLOGIC CORPORATION (NASDAQ: QUIK)

Technology | Market Cap: \$120M

QuickLogic Corporation (NASDAQ: QUIK) is a fabless semiconductor company that develops low power, multi-core semiconductor platforms and Intellectual Property (IP) for Artificial Intelligence (AI), voice and sensor processing. The solutions include embedded FPGA IP (eFPGA) for hardware acceleration and pre-processing, and heterogeneous multi-core SoCs that integrate eFPGA with other processors and peripherals. The Analytics Toolkit from our recently acquired wholly owned subsidiary, SensiML Corporation, completes the end-to-end solution with accurate sensor algorithms using AI technology. The full range of platforms, software tools and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across mobile, wearable, hearable, consumer, industrial, edge and endpoint IoT. For more information, visit www.quicklogic.com.

RELIQ HEALTH TECHNOLOGIES INC. (TSXV: RHT / OTC PINK: RQHTF)

Healthcare | Market Cap: \$71M

Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq's powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits.

REVIVA PHARMACEUTICALS HOLDINGS (NASDAQ: RVPH)

Healthcare | Market Cap: \$91M

Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently includes two drug candidates, brilroxazine (RP5063) and RPI208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilroxazine and RPI208 in the United States (U.S.), Europe, and several other countries.

RILEY EXPLORATION PERMIAN, INC. (NYSE AMERICAN: REPX)

Energy | Market Cap: \$700M

Riley Permian is a growth-oriented, independent oil and natural gas company focused on the acquisition, exploration, development and production of oil, natural gas and NGLs. Our activities primarily target the horizontal development of the San Andres and Yeso formations, conventional shelf margin deposits on the Northwest Shelf of the Permian Basin. The majority of our acreage is located on large, contiguous blocks in Yoakum County, TX. and Eddy County, NM. Low base-decline assets enable less capital-intensive reinvestment to maintain and grow production, and in turn, more capital available to return to shareholders.

S&W SEED COMPANY (NASDAQ: SANW)

Industrials | Market Cap: \$52M

Founded in 1980, S&W Seed Company is a global integrated seed technology company focused on middle market crops. Headquartered in the United States and with operations in Australia, S&W's vision is to be the world's preferred proprietary seed Company which supplies a range of forage and specialty crop products that supports the growing global demand for animal proteins and healthier consumer diets. S&W is a global leader in proprietary alfalfa, sorghum and pasture seeds, with significant research and development, production and distribution capabilities. S&W's product portfolio also includes hybrid sunflower and wheat and the company is utilizing its research and breeding expertise to develop and produce stevia, the all-natural, zero calorie sweetener for the food and beverage industry.

SATURN OIL & GAS INC. (TSX: SOIL / OTCQX: OILSF)


Energy | Market Cap: \$272M

Saturn Oil & Gas is a growing Canadian energy company focused on generating positive shareholder returns through the continued responsible development of high-quality, light oil weighted assets, supported by an acquisition strategy that targets highly accretive, complementary opportunities. The Company has assembled an attractive portfolio of free-cash flowing, low-decline operated assets in Central Alberta, Southeastern Saskatchewan and West Central Saskatchewan that provide a deep inventory of long-term economic drilling opportunities across multiple zones. With an unwavering commitment to building an ESG-focused culture, Saturn's goal is to increase reserves, production and cash flows at an attractive return on invested capital.



COMPANY PROFILES

Market Cap data (\$USD) updated as of 9.1.23



SCIENTIFIC INDUSTRIES, INC. (OTCQB: SCND)

Healthcare | Market Cap: \$32M

Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the product name Cell Growth Quantifier and Liquid Injection System. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com. Scientific Bioprocessing, Inc. ("SBI") is dedicated to providing state-of-the-art instruments, strategies, and technologies to expedite the production of viable cells and therapies with a streamlined process and product consistency. SBI's mission is to develop sensor technologies and instruments that make cell culture and bioprocessing work easier, experiments more reproducible, and culture conditions better suited to meet experimental objectives. SBI is a subsidiary of Scientific Industries Holdings, Inc. To learn more, visit www.scientificbio.com.

SENESTECH (NASDAQ: SNES)

Industrials | Market Cap: \$2M

SenesTech is "The Pest Control Difference" for the 21st century. They are rodent fertility control specialists fueled by our passion to create a healthy environment by virtually eliminating rodent pest populations. We keep an inescapable truth in mind. Two rats can be responsible for the birth of up to 15,000 pups a year. SenesTech invented ContraPest®, the world's first and only U.S. EPA registered rodent contraceptive. ContraPest® fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rodent management. We strive for clean cities, efficient businesses and happy households—all through non-lethal, proactive pest control. At SenesTech, they don't just eliminate rats. They make a better world.

SHUTTLE PHARMACEUTICALS, INC. (NASDAQ: SHPH)

Healthcare | Market Cap: \$12M

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy.

SKYX PLATFORMS CORP. (NASDAQ: SKYX)

Technology | Market Cap: \$166M

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX Platforms Corp. has a series of highly disruptive advanced-safe-smart platform technologies, with over 60 U.S. and global patents and patent pending applications. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at SKYXPlatforms.com or follow us on LinkedIn.

SOBR SAFE, INC. (NASDAQ: SOBR)

Healthcare | Market Cap: \$25M

The annual cost of alcohol abuse in the U.S. is \$249 billion. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers test positive for alcohol (the highest rate worldwide). In response, SOBRsafe; has developed a proprietary, touch-based identity verification, alcohol detection and cloud-based reporting system. The technology is transferable across innumerable form factors, including stationary access control, personal wearables and telematics integration. A preventative solution in historically reactive industries, it is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This patent-pending alcohol detection solution helps prevent an intoxicated worker from taking the factory floor or a driver from receiving the keys to a truck, bus or the family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions. At SOBRsafe, we are creating a culture of prevention and support. To learn more, visit www.sobrsafe.com.

SOCIETY PASS INCORPORATED (NASDAQ: SOPA)


Technology | Market Cap: \$20M

As a digitally-focused loyalty and data marketing ecosystem in Vietnam, Indonesia, Philippines, Singapore and Thailand and with offices located in Bangkok, Hanoi, Ho Chi Minh City, Jakarta, Manila, and Singapore, Society Pass Inc (Nasdaq: SoPa) is an next generation, acquisition-focused fintech and e-commerce holding company operating 6 interconnected verticals (loyalty, lifestyle, F&B delivery, telecoms, digital media, and travel), which seamlessly connects millions of registered consumers and hundreds of thousands of registered merchants/brands across multiple product and service categories throughout SEA. SoPa's business model focuses on analysing user data through its Society Pass loyalty platform and circulation of its universal loyalty points or Society Points. The Society Pass loyalty platform drives customer acquisition and increases customer retention for merchants. Since its inception, SoPa has amassed over 3.3 million registered consumers and over 650,000 registered merchants/brands onto its platform. SoPa leverages technology to tailor a more personalised experience for customers in the purchase journey and to transform the entire retail value chain in SEA. SoPa operates Leflair.com, Vietnam's leading lifestyle e-commerce platform; Pushkart.ph, a popular grocery delivery company in Philippines; Handycart.vn, a leading Vietnam-based restaurant delivery service; Mangan, a leading local restaurant delivery service in Philippines; Gorilla Networks, a Singapore-based, web3-enabled mobile blockchain network operator; Thoughtful Media Group, a Bangkok-based, a social commerce-focused, premium digital video multi-platform network, and NusaTrip, a leading Jakarta-based online travel agency in Indonesia and across SEA. On 09 November 2021, Society Pass Inc. successfully completed its IPO and debuted its listing on Nasdaq Capital Market as SOPA.



COMPANY PROFILES

Market Cap data (\$USD) updated as of 9.1.23



VERSES AI INC. (CBOE: VERS / OTCQX: VRSSF)

Technology | Market Cap: \$101M

VERSES is a cognitive computing company specializing in next-generation Artificial Intelligence. Modeled after natural systems and the design principles of the human brain and the human experience, VERSES flagship offering, GIA™, is an Intelligent Agent for anyone powered by KOSM™, a network operating system enabling distributed intelligence. Built on open standards, KOSM transforms disparate data into knowledge models that foster trustworthy collaboration between humans, machines, and AI, across digital and physical domains. Imagine a smarter world that elevates human potential through innovations inspired by nature.

VOLT LITHIUM CORP. (TSXV: VLT / OTCQB: VLTLF)

Basic Materials | Market Cap: \$15M

Volt is a lithium development and technology company aiming to be North America's first commercial producer of lithium hydroxide and lithium carbonates from oilfield brine.

WINDTREE THERAPEUTICS, INC. (NASDAQ: WINT)

Healthcare | Market Cap: \$5M

Windtree Therapeutics, Inc. is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with our lead candidate, istaroxime, being developed as a first in class treatment for cardiogenic shock and acute heart failure. Windtree's heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. Included in Windtree's portfolio is rostafuroxin, a novel drug product targeting the treatment resistant hypertension disease state for patients with certain genetic profiles.

WONDERFI TECHNOLOGIES INC. (TSX: WNDR / OTCQB: WONDF)

FinTech | Market Cap: \$83M

WonderFi aims to revolutionize access to digital assets by operating its three registered Canadian-owned and operated crypto asset trading platforms: Bitbuy, Coinsquare, and CoinSmart. With a collective user base of over 1.6 million registered Canadians and a combined assets under custody exceeding \$730 million, WonderFi boasts one of the largest communities of crypto investors within a single regulated ecosystem in Canada.

ZOMEDICA CORP. (NYSE AMERICAN: ZOM)

Healthcare | Market Cap: \$168M

Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care.

ZOOMD TECHNOLOGIES (TSXV: ZOMD / OTC PINK: ZMDTF)

Technology | Market Cap: \$4M

Zoomd (TSXV: ZOMD) (OTC: ZMDTF), founded in 2012 and began trading on the TSX Venture Exchange in September 2019, offers a site search engine to publishers, and a mobile app user-acquisition platform, integrated with a majority of global digital media, to advertisers. The platform unifies more than 600 media sources into one unified dashboard. Offering advertisers, a user acquisition control center for managing all new customer acquisition campaigns using a single platform. By unifying all these media sources onto a single platform, Zoomd saves advertisers significant resources that would otherwise be spent consolidating data sources, thereby maximizing data collection and data insights while minimizing the resources spent on the exercise. Further, Zoomd is a performance-based platform that allows advertisers to advertise to the relevant target audiences using a key performance indicator-algorithm that is focused on achieving the advertisers' goals and targets.



DISCLAIMERS / DISCLOSURES

Services: Lytham Partners, LLC ("Lytham") provides a range of investor relations services to its clients. The particular services provided vary by client and may change from time to time. Compensation Information: Lytham is compensated by its clients for providing investor relations services. Click here for full compensation information: <https://lythampartners.com/disclosures/>. No Investment Advice: Lytham is not a registered broker-dealer, registered investment adviser or financial adviser, nor does it hold itself out to be. All materials presented on Lytham's website and/or publications or presentations released by Lytham to the public through its website, email, or any other means of transmission are not to be regarded as investment advice, do not constitute an endorsement of the company, and are only for informative purposes. Before making a purchase or sale of any securities mentioned in Lytham's publications or presentations or on its website, Lytham strongly encourages and recommends consultation with a registered securities representative. Lytham's website and/or publications or presentations released by Lytham to the public through its website, email, or any other means of transmission do not constitute an offer to purchase or sell securities, and is not to be construed as a representation of an offer or a solicitation of any offer by Lytham or its client companies to purchase or sell any security. Lytham or any of its affiliates, members, employees, clients, officers, directors, and/or their respective families may from time to time purchase or sell, as agents or principals, or otherwise hold positions in, securities of its client companies, and are free to buy or sell those positions at will. Any such positions may be increased or decreased from time to time in the future without notice. Any information or opinions expressed on Lytham's website and/or publications or presentations released by Lytham are subject to change without notice. Lytham's full disclaimer/disclosures statement can be found on its website at <https://lythampartners.com/disclosures/>.

